CSL Limited (ASX: CSL)Share Price and News
About CSL
CSL is a multinational biotech powerhouse headquartered in Melbourne and one of the largest companies on the ASX (currently 8th although it was briefly 1st in early 2020). It is easily the largest healthcare company on the Australian bourse.
CSL, has two primary businesses: flu vaccines and blood products. In the latter instance, it takes plasma from donors and turns it into life-saving therapeutics, particularly immunoglobin products. Plasma is the substance that carries red and white blood cells through the body – these therapies are relevant for disorders such as hemophilia, primary immune deficiencies, hereditary angioedema and inherited respiratory disease.
The company makes and sells other drugs too. To this end it has an extensive R&D division that develops drugs. One of its latest is Hemgenix, the first gene therapy for the treatment of Hemophilia B.
CSL's Company History
CSL stands for Commonwealth Serum Laboratories, originally established during World War One to produce vaccines and antivenoms for the Australian public. The company has a proud history, enabling many of the 20th century medical advances to reach our shores such as insulin, penicillin and flu vaccines.
The transition to a publicly listed entity occurred in 1994, marking the start of CSL's transformation into a global biopharmaceutical company. Its 1994 IPO was done at A$2.30 per share, and a 3 for 1 stock split in 2007 means those original shares are about $0.77 each.
A pivotal moment in CSL's history was its acquisition of Novartis' influenza vaccine business in 2015, rebranded as Seqirus. This move significantly expanded CSL's footprint in vaccines, complementing its plasma therapies and strengthening its position in the global health market.
Another moment came in late 2021 when it bought Vifor, a Swiss renal therapy and iron deficiency products company. It paid a whopping US$11.7bn and investors have been skeptical that it has obtained (or that it ever will obtain) a value for money.
Ever since, it has been difficult times for the company. It has been plagued by fears over weight-loss drugs and their potential to possibly reduce the size of CSL's markets, with the logic being if you cut obesity, you cut the incidence of related conditions. It is failing to see the payoff from Vifor that was promised, anti-vaxxer sentiment in the US is hurting its business, margin problems in the Behring business and there's a perception the company has no idea how to turn things around.
CEO Paul McKenzie departed in early 2026 after 3 unsuccessful years and was replaced by Gordon Naylor on an interim basis
CSL's Future Outlook
For FY26, CSL has provided detailed guidance that management anticipates delivering group revenue growth of about 4–5% over FY25 at constant currency, supported by ongoing global demand for therapies, expanding product uptake and operational initiatives. On an earnings basis, the company expects NPATA (net profit after tax and amortisation, excluding significant restructuring items) of roughly US$3.45bn– US$3.55bn, which would represent around 7–10% growth compared with the prior year.
As part of its strategic repositioning, CSL is implementing major organisational changes, including simplifying its operating model, improving R&D productivity, reducing fixed costs and planning to demerge its CSL Seqirus vaccine business into a separate ASX‑listed entity before the end of FY26, although timing has been revised amid market volatility.
All things considered, we think long‑term fundamentals remain supported by global demand for plasma therapies, an expanding specialty medicines portfolio and strategic initiatives designed to streamline the business and renew growth momentum. But investors won't send the stock back to early 2020s levels without clear evidence things are improving.
Is CSL (ASX: CSL) a Good Stock to Buy?
CSL may be attractive for investors seeking exposure to global biopharmaceutical leadership, recurring demand from essential therapies and a strong balance sheet, particularly if long‑term growth and dividends are priorities. However, the stock’s near‑term outlook carries uncertainty due to softer guidance, strategic restructuring and competitive dynamics, so it is typically better suited to long‑term investors with tolerance for biotech sector cyclicality rather than short‑term traders.
The company’s recent guidance revision and structural reshaping have been met with shareholder frustration and resulted in material share price weakness from historical highs. The deceleration in the U.S. influenza vaccine market has directly impacted near‑term revenue expectations for the Seqirus segment and contributed to reduced growth forecasts for FY26 (now around 2–3% to 4–5% growth depending on how recent adjustments are interpreted).
CSL’s stock has also experienced broader volatility as investors re‑evaluate valuations and weigh long‑term prospects against short‑term execution risk. In markets where biotech multiples contract or healthcare investors rotate out, CSL could underperform relative to broader indices despite solid business fundamentals.
Our Stock Analysis
Here are 6 of the best results this ASX reporting season (so far), and 6 of the worst!
This article recaps some of the best results this ASX reporting season so far, as well as some of the…
Here are some ASX stocks that will benefit from a higher AUD, and stocks that will lose
The Aussie dollar has been surging in recent weeks and there are ASX stocks that will benefit from a higher…
Why ASX Healthcare Stocks Are Crashing- and Which One Looks Like a Buy
ASX healthcare stocks are crashing- which one is worth buying now? Three of Australia’s most premium ASX healthcare stocks have…
CSL CEO Paul McKenzie has departed, now what for the fallen biotech giant?
In a bombshell 4pm announcement, investors learned that CSL CEO Paul McKenzie was departing the company effective that very afternoon…
CSL Cuts FY26 Guidance And Plunges 20% (What Investors Need to Know)
CSL Cuts FY26 Guidance, Shattering Investor Confidence CSL surprised investors today as its share price dropped around 20% following its…
6 Trends on ASX Company Boards That Should Raise Investor Eyebrows
Last week, Ownership Matters released a major report on ASX Company Boards. The report, studied ASX 300 entities (excluding ‘stapled…
Frequently Asked Questions
CSL offers a dividend yield near 1.1%, backed by a consistent history of dividend growth, reflecting strong cash flow and management's commitment to shareholder returns.